Image of a doctor speaking to a patient on navy background with royal blue hash pattern overlay

For Interventional Cardiologists

Your source of training and data to treat high-risk PCI, cardiogenic shock and right heart failure patients

Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Report Demonstrate Benefit of Early Impella Cardiac Unloading

The final results of the physician-led NCSI Study demonstrate a 71% survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization (PCI).

Explore the Latest Presented Data From the National Cardiogenic Shock Initiative (NCSI) Study

  • 71%


  • >90%

    Native heart recovery at discharge1

NCSI Study is an independent, physician-led, national, multicenter initiative aimed at improving mortality in patients with AMI cardiogenic shock (AMICS).1 Based on the consistent finding of good survival outcomes with early hemodynamic support with Impella therapy from the IQ database and cVAD study, a best practices algorithm for the treatment of patients with AMICS was established. The NCSI Study algorithm includes identifying shock early, use of Impella therapy before PCI, reducing the use of inotropes, and the use of invasive hemodynamic monitoring to aid in escalation and weaning.

As of April 2021, 406 patients with AMI cardiogenic shock from 80 participating sites treated using Impella best practices demonstrated 71% survival at discharge with more than 90% native heart recovery.1

View Additional NCSI Study Resources


Achieving >70% AMICS Survival: Insights From National Cardiogenic Shock Initiative Study

William O'Neill, MD, discusses the application of best practices from the NCSI Study.


About 40% of AMICS Patients Develop Right Ventricular Dysfunction

Babar Basir, DO, discusses findings on right heart dysfunction from the NCSI Study.


Efficacy and Safety of all Impella Heart Pump Use in Japanese Patients With Drug-Resistant Acute HF

Junya Ako, MD, presents the interim analysis of data from 819 patients from the Japanese Registry for Percutaneous VAD (J-PVAD). J-PVAD is an investigator-initiated, prospective study of all Impella use in Japan with the goal to safely and effectively disseminate the use of Impella with appropriate use guidance.

White illustration of a screen showing graphs

Education and Resources

Explore case reviews, clinical data, ongoing studies, best practice resources, patient management tips and more

White illustration of a hand pointing at a phone with a medical cross

Calculators and Tools

Access instant calculators for CPO/PAPI, heparin rate and AKI, and identify patients using the selection tool

Subscribe to receive the latest clinical data and priority access to resources.


  1. Basir, B., et al. (2021). SCAI Scientific Sessions


This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].